Bristol-Myers Squibb Co
BMYView Detailed Chart
55.300USD
-1.890-3.30%
Close 04/04, 16:00（ET）Quotes delayed by 15 min
110.93BMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-3.30%
5 Days
-7.86%
1 Month
-7.55%
6 Months
+2.48%
Year to Date
-2.22%
1 Year
+7.75%
View Detailed Chart
Agency Rating
Analyst Rating
Based on
27
analysts
HOLD
Current Rating
59.725
Target Price
8.00%
Rising Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
150
Total
5
Median
7
Average
Company name
Ratings
Analysts
Bristol-Myers Squibb Co
BMY
27
Biogen Inc
BIIB
37
Alnylam Pharmaceuticals Inc
ALNY
33
Amgen Inc
AMGN
33
Gilead Sciences Inc
GILD
30
BioMarin Pharmaceutical Inc
BMRN
29
1
2
3
...
30
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Sell
Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.962
Neutral
RSI(14)
34.262
Neutral
STOCH(KDJ)(9,3,3)
16.374
Sell
ATR(14)
1.672
High Vlolatility
CCI(14)
-310.813
Oversold
Williams %R
91.329
Oversold
TRIX(12,20)
0.088
Sell
StochRSI(14)
0.000
Oversold
Moving Average
Indicators
Value
Direction
MA5
58.642
Sell
MA10
59.159
Sell
MA20
59.570
Sell
MA50
58.409
Sell
MA100
57.856
Sell
MA200
52.808
Buy
News
More news coming soon, stay tuned...
Company
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its platforms comprise chemically synthesized or small molecule drugs, including protein degraders; drugs produced from biological processes, called biologics; ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are also used. Biologics are typically administered through injections or by intravenous infusion. CAR-T cell therapies are administered by intravenous infusion. Its growth portfolio includes Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Opdualag, and others. Its legacy portfolio includes Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel and Abraxane.
Company codeBMY
CompanyBristol-Myers Squibb Co
CEODr. Christopher S. (Chris) Boerner, Ph.D.
Websitehttps://www.bms.com/in
